Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee
Cellular therapies, namely autologous hematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) and more recently, chimeric antigen receptor T-cell therapies (CART), play a major role in state-of-the‑art treatment of mantle cell lymphoma (MCL).
Cellular therapies, namely autologous hematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) and more recently, chimeric antigen receptor T-cell therapies (CART), play a major role in state-of-the‑art treatment of mantle cell lymphoma (MCL).
The article provides updated recommendations for the use of cellular therapies in mantle cell lymphoma, a high‑grade B‑cell lymphoma with historically poor outcomes, thereby guiding clinicians on optimal sequencing and indication for therapies such as auto‑HCT, allo‑HCT and CAR‑T products.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology
- Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.
- Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa